Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
18.11.2020 15:00:00 EET | Business Wire | Press release
Agendia, Inc., a world leader in precision oncology for breast cancer, and Paige, a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai, https://www.paigeplatform.com , Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Contact information
For Media:
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
For Agendia Investors:
Mike Cavanaugh
Westwicke/ICR Healthcare IR
Tel: 617.877.9641
Mike.Cavanaugh@westwicke.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unimed Expands Maritime Healthcare Platform with Growing Adoption of Telemed Plus13.8.2026 12:00:00 EEST | Press release
Universal Maritime Solutions (“Unimed” or “the Company”), a leading provider of maritime healthcare, medical supply, and crew wellbeing solutions and a portfolio company of ZCG Private Equity, the private equity fund management platform of Z Capital Group, LLC (“ZCG”), today announced that Bahri, one of the Middle East’s leading maritime operators, has expanded its relationship with Unimed by enrolling in its Telemed Plus premium service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813787745/en/ The agreement builds on a longstanding relationship between the companies through Unimed’s MedScale medical supply and medical chest management program and marks another important milestone in the continued rollout of Unimed’s Telemed Plus platform, launched in 2024. The expansion underscores the growing adoption of Unimed’s integrated healthcare platform by leading global maritime operators while demonstrating the increasing v
The Fairest of Them All: Klarna Supercharges Memberships, Removing Fees, Boosting Cashback and Increasing Annual Value to as Much as €6,00013.8.2026 10:09:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, today unveiled its most significant membership upgrade yet. The revamped tiers deliver more cashback, up to €6,000 worth of perks, and remove service fees — built so a Klarna membership pays for itself, and then some. Klarna's improved membership lineup spans four tiers, each built for a different kind of member but all embodying a flexible ethos: pay only for the Klarna that fits your life. Pay later is free at partner stores, or get broader fee-free access with Everywhere (formerly Core), or climb to Plus, Premium or Max for richer cashback rewards, bigger, everyday perks and a growing set of subscriptions and protections. A Klarna membership is a fairer alternative to a credit card by design, and one of the biggest differences is freedom. While other cards tie you in for a year, a Klarna membership moves with you. Upgrade for a big travel month and drop back down when things are quieter, with no penalty and no year-long
Interactive Brokers Adds Access to the Bucharest Stock Exchange, Offering Access to One of Europe's Strongest-Performing Markets of 202513.8.2026 10:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced access to the Bucharest Stock Exchange (BVB). This expansion offers access to one of Europe’s strongest-performing emerging markets of 2025, expanding diversification opportunities for IBKR clients alongside over 170 other global exchanges on a single, advanced platform. Romania was elevated to MSCI’s Advanced Frontier Market status while the BET index reached record highs in 2025 and continued its growth through the first half of 2026. With this integration, IBKR clients can access Romanian equities through the same platform they use for markets worldwide, making it easier to incorporate Romanian listed companies into their global investment strategies. “Adding the Bucharest Stock Exchange expands the choices available to our clients and reinforces our commitment to providing the broadest possible access to global markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Romania is one o
Lenovo Group: Q1 Financial Results 2026/2713.8.2026 07:16:00 EEST | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported first quarter results for fiscal year 2026/27, marking the highest quarterly revenue growth in the past five years and the strongest quarter in the Group’s history. During the quarter, overall Group revenue reached an all-time quarterly high of US$26.9 billion, up 43% year-on-year, with all business groups delivering record first-fiscal-quarter revenue and operating profit. Adjusted net income[1]was up 176% year-on-year to US$1.1 billion, surpassing the US$1 billion milestone for the first time ever, with adjusted net margin improvements of almost two percentage points year-on-year supported by higher revenue scale and continued efficiency gains. AI-related revenue[2] grew 60% year-on-year to US$9.3 billion, accounting for 35% of total Group revenue in Q1. The Group continues to invest in innovation with R&D expenses up 30% year-on-year. The first quarter results demonstrate the G
Suzano Reports Adjusted EBITDA of R$4.7 Billion in the Second Quarter of 202613.8.2026 02:27:00 EEST | Press release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2026 (2Q26), reporting higher prices, stronger volumes and improvements in Adjusted EBITDA and operating cash generation compared to the previous quarter. The quarterly results reflect the competitiveness and resilience of Suzano’s operations in a quarter marked by foreign exchange headwinds and pressure on input costs driven by higher oil prices affecting the industry as a whole. Suzano sold 3.3 million tonnes of pulp and paper combined in 2Q26, comprising 2.9 million tonnes of pulp and 406 thousand tonnes of paper across the packaging, printing and writing, specialty and tissue segments. Net revenue totalled R$11.6 billion and adjusted EBITDA reached R$4.7 billion, both above the levels recorded in the previous quarter. Operating cash generation reached R$2.9 billion, while net income totalled R$1.8 billion in 2Q26. Despite ongoing cost pressures, the cash cost of pulp production (excluding dow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom